Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge
U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday.
US Stocks Mixed; Dow Jumps 200 Points
U.S. stocks traded mixed this morning, with the Dow Jones surging around 200 points on Monday.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
Applied Genetic Techs (NASDAQ:AGTC) shares moved upwards by 62.0% to $0.39 during Monday's pre-market session. The company's market cap stands at $26.3 million.
Vaxcyte Completes Enrolment In Mid-Stage Pneumococcal Disease Study, Sees Top-line Data In H1 2013
Vaxcyte (NASDAQ: PCVX) has completed patient enrollment in the Phase 2 study evaluating VAX-24 in healthy adults 65 years of age and older.
VAX-24 is its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).
Vaxcyte Concludes Enrolment In Mid-Stage Pneumococcal Disease Study
Vaxcyte (NASDAQ: PCVX) completed patient enrollment in the Phase 2 portion of the ongoing Phase 1/2 proof-of-concept study evaluating VAX-24 in healthy adults 50 to 64 years of age.
Vaxcyte Completes Enrollment Of Phase 2 Portion Of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability And Immunogenicity Of VAX-24 In Adults
Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults
-- Company Expects to Announce Topline Results from the
Vaxcyte Doses First Participants In Phase 2 Portion Of Ongoing VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study In Adults
-- Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned --
-- Company Expects to Announce Topline Results from Both the Phase 1
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.